Please login to the form below

Not currently logged in
Email:
Password:

Shire separates out neuroscience as it considers its future

Follows last year's strategic review at the Irish biotechnology firm

Shire

Shire has decided its neuroscience business would do better as a separate division and will move it out from its rare disease interests following a five-month strategic review.

The move raises speculation that it’s a precursor to the unit’s divestment, particularly given Shire’s stated strategy of becoming ‘the leading global biotech company focused on rare diseases’.

Commenting on the change the Irish biotech said there was a strong business rationale for creating the two divisions, given their “distinct strategic priorities”.

In a statement that company said it was “continuing to evaluate all strategic alternatives, including the merits of an independent listing for each of the two divisions”, with the review’s second stage expected to report before the end of the year.

Historically dependent on just one ADHD treatment - Adderall -, neuroscience has dwindled in the face of Shire’s rising presence in orphan drugs and last year it accounted for less than a quarter of the firm’s $11bn revenue.

The company also faces outside pressures, and shortly before Christmas was mentioned in the press as a possible big pharma takeover target after the failure of a pivotal trial for its Hunter syndrome therapy.

The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the US.

Meanwhile, Shire’s rare disease business - which accounts for 70% of revenues - has been growing apace, receiving a significant boost from the $32bn merger with Baxalta in 2016.

CEO Flemming Ornskov said: “Shire has undergone a significant transformation over the last five years creating two market-leading businesses with distinct profiles and future needs.

“Simultaneously, Shire has established a strong track record of growth and execution. Our new Rare Disease and Neuroscience Divisions will be well positioned for growth, profitability, innovation, and serving the needs of patients.”

Shire’s announcement came just days after pharma giant Pfizer exited early-stage Alzheimer’s and Parkinson’s R&D to allow it to make more effective use of its neuroscience research investments.

Article by
Dominic Tyer

9th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics